ArticlePharmaceuticals (Basel, Switzerland)2026
Multitargeting Pt(IV) Anticancer Prodrugs Bearing Mono- and Bis-Probenecid Ligands in Axial Positions: Synthesis and Evaluation of Biological Activity.
Panxing Qiu, Yu Zhang, Yang Dou, Zhijin Cheng, Xiaoqin Wu, Silong Zhang, Fuyi Wang, Kui Wu
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Panxing QiuKey Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, China.
Yu ZhangSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Yang DouBeijing National Laboratory for Molecular Sciences, National Centre for Mass Spectrometry in Beijing, CAS Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Zhijin ChengKey Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, China.
Xiaoqin WuKey Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, China.
Silong ZhangSchool of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, China.
Fuyi WangBeijing National Laboratory for Molecular Sciences, National Centre for Mass Spectrometry in Beijing, CAS Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.ORCID 0000-0003-0962-1260 Kui WuKey Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, China.ORCID 0000-0002-4995-0395 Funding
Hubei Key Laboratory of Bioinorganic Chemistry & Materia Medica BCMM202305the Department of Education of Hubei Province B2022021the Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials WKDM202304Wuhan University of Science and Technology 040274
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
anticancermetallodrugmultitargetingprobenecidPt(IV) prodrug
Identifiers
PMID41901232
PMCPMC13029561
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390